{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-086030","form_type":"8-K","ticker":"MRK","cik":"0000310158","company_name":"Merck & Co., Inc.","filed_at":"2023-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.223631+00:00","generated_at":"2026-06-12T19:26:18.779759+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Merck posts Q2 GAAP loss of $5.98B on $10.2B Prometheus charge; raises FY sales outlook","bullets":["GAAP loss per share of $2.35 on net loss of $5,975M; includes $4.02/share charge for Prometheus acquisition.","Total sales $15,035M (+3% YoY); excluding LAGEVRIO, sales grew 11% (+14% ex-FX).","KEYTRUDA sales $6,271M (+19% YoY); GARDASIL/GARDASIL 9 sales $2,458M (+47% YoY).","LAGEVRIO sales fell 83% to $203M; non-GAAP EPS loss of $2.06 vs. $1.87 gain a year ago.","FY 2023 sales outlook raised to $58.6-59.6B; non-GAAP EPS outlook $2.95-3.05 (includes -$4.53/share one-time charges)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-086030","json":"https://secwatch.observer/filing/0001104659-23-086030.json","markdown":"https://secwatch.observer/filing/0001104659-23-086030.md","text":"https://secwatch.observer/filing/0001104659-23-086030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/310158/000110465923086030/0001104659-23-086030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/310158/000110465923086030/tm2322190d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T19:26:18.779759+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"083b0b8fa8aa2414a050315246bf78a15e556223","claim":"Merck & Co., Inc. reported the second quarter of 2023 results: revenue $15.0 Billion, net income $(5,975) million, EPS ($2.35) per share. Guidance raised.","evidence_excerpt":"Merck Announces Second-Quarter 2023 Financial Results - Sales Reflect Sustained Underlying Growth, Particularly in Oncology and Vaccines - Total Worldwide Sales Were $15.0 Billion, an Increase of 3% From Second Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of Foreign Exchange, Growth Was 14% ○ KEYTRUDA Sales Grew 19% to $6.3 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 21% ○ GARDASIL/GARDASIL 9 Sales Grew 47% to $2.5 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 53% ○ LAGEVRIO Sales Declined 83% to $203 Million; Excluding the Impact of Foreign Exchange, Sales Declined 82% - GAAP Loss per Share Was $2.35; Non-GAAP Loss per Share Was $2.06; GAAP and Non-GAAP Loss per Share Include a Charge of $4.02 per Share for the Acquisition of Prometheus - Presented Compelling Data in Earlier Stages of Cancer at 2023 ASCO Annual Meeting, Including: o Positive Phase 3 Results From KEYNOTE-671 Trial o Promising New Data From Phase 2","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/310158/000110465923086030/0001104659-23-086030-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of 2023"},{"label":"Revenue","value":"$15.0 Billion"},{"label":"Net income","value":"$(5,975) million"},{"label":"EPS","value":"($2.35) per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}